Own previous work revealed that cells with overexpression of the clinically relevant PH-domain mutant AKT1-E17K with aberrant activation of AKT accelerated DSB repair and improved the survival of TRAMPC1 prostate cancer cells (TrC1) upon IR (33). This evidence concerns the gene AKT1 and prostate carcinoma.